Agios to Present New Data from PKR and IDH Programs at the 2016 ASH Annual Meeting
- Updated Safety and Efficacy Data from
Portion of AG-120 Study to be Highlighted in Oral and Poster Presentations -
- Company to Host Investor Event and Webcast on
In total, five abstracts led by Agios describing new clinical data from the company’s cancer metabolism and rare genetic metabolic disorders programs have been accepted for presentation at ASH. Two additional abstracts from
The accepted abstracts are listed below and are now available online on the ASH conference website: https://ash.confex.com/ash/2016/webprogram/start.html
Oral Presentations
Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients With Pyruvate Kinase Deficiency: Data From the DRIVE PK Study
Date & Time:
Session Title: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Anemia and Disordered Erythropoiesis
Abstract Number: 402
Location:
Determination of IDH1 Mutational Burden and Clearance via Next-Generation Sequencing in Patients With
Date & Time:
Session Title: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: FLT3 and IDH Targeted Therapies in AML
Abstract Number: 1070
Location:
Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)
Date & Time:
Session Title: 637. Myelodysplastic Syndromes—Clinical Studies: Higher Risk MDS Clinical Studies
Abstract Number: 343
Location: Manchester Grand Hyatt San Diego, Grand Hall C
Poster Presentations
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of AG-519, an Allosteric Activator of Pyruvate Kinase-R, in Healthy Subjects
Date & Time:
Session Title: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster I
Abstract Number: 1264
Location:
Population Pharmacokinetics and Pharmacodynamics of AG-519, a Pyruvate Kinase Activator for the Treatment of Pyruvate Kinase Deficiency, in
Date & Time:
Session Title: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster I
Abstract Number: 1263
Location:
Characterization of Metabolic Response to AG-348, an Allosteric Activator of Red Cell Pyruvate Kinase, in
Date & Time:
Session Title: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster II
Abstract Number: 2452
Location:
Iron Overload is Highly Prevalent in All Disease Severity States in Pyruvate Kinase Deficiency (PKD)
Date & Time:
Session Title: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster II
Abstract number: 2430
Location:
Investor Event and Webcast Information
Agios will host an investor event on
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic metabolic disorders through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential of IDH1/IDH2 and pyruvate kinase-R mutations, or other mutations, as therapeutic targets; the potential benefits of Agios' product candidates targeting IDH1/IDH2 or pyruvate kinase-R mutations or other genetic mutations, including
Agios Pharmaceuticals :Kendra Adams , 617-844-6407 Senior Director, Investor & Public Relations Kendra.Adams@agios.comRenee Leck , 617-649-8299 Senior Manager, Investor & Public Relations Renee.Leck@agios.com